The hope for neglected diseases: R&D incentives

Neglected diseases are neglected because they cannot generate enough return on R&D to pharmaceutical firms. This paper analyzes and compares existing proposals for public intervention in R&D for neglected diseases. Incentives for neglected diseases are comprehensively evaluated based on seventeen selected criteria grouped into four categories: efficiency, feasibility, fairness, and sustainability. Our conclusion is that public-private partnerships coordinated through a centralized service platform have the highest potential to satisfy the criteria for the successful development..